



Role of Radiotherapy in Painful Bone metastases

Jiraporn Setakornnukul, M.D.

Radiation oncology division,



Radiology department

Siriraj Hospital, Mahidol University





What is Radiotherapy?





Goals of palliative treatment of bone metastases


- Pain relief
- Preservation of function
- Stabilized involved bone
- Decrease progressive bone loss
- Decrease or eliminate tumor proliferation







Radiotherapy in painful bone metastases

Conventional radiotherapy for spinal metastases

Conventional radiotherapy techniques for treatment of spine metastases



Single posterior field
1 x 8Gy 10 x 3Gy





Radiotherapy in painful bone metastases

- Localized bone pain, radiotherapy is considered the standard treatment modality

Response of radiotherapy

- Overall pain relief with a 60–80% response was reported within 3 to 4 weeks
- Some patients the onset of pain relief is rapid, within days
- 40% of patients a temporary pain flare occurs
 - two-point increase of the worst pain score



Meta-analysis: multiple vs single fraction

- 30 Gy in 10 fractions (3Gy/F)
- 24 Gy in 6 fractions (4Gy/F)
- 20 Gy in 5 fractions (4Gy/F)
- 8 Gy in 1 fraction


| | Single Fraction | Multiple Fractions | P Value |
|----------------------|-----------------|--------------------|----------|
| Overall Response | 58% | 59% | 0.60 |
| Complete Response | 23% | 24% | 0.51 |
| Pathologic Fracture* | 3.2% | 2.8% | 0.75 |
| Cord Compression* | 2.8% | 1.9% | 0.13 |
| Retreatment | 20% | 8% | <0.00001 |



Radiotherapy in painful bone metastases



Conventional radiotherapy for spinal metastases

Conventional radiotherapy
for treatment of painful bone metastases



- Pain response after conventional RT: ~70%
- HOWEVER, pain control after 3 – 6 months: ~35%

Complete pain response is achieved in only 25 – 40% of the patients





Stereotactic **B**ody **R**adio**T**herapy (SBRT) **S**tereotactic **A**Blative **R**adiotherapy (SABR)

= high dose radiation per day ($\geq 7-10$ Gy)

= small number of fraction (≤ 10 fractions)







Advanced Radiation Technique



- Immobilization



- Planning system & Radiotherapy Machine & IGRT





ASTRO guideline for SBRT-spine

Table 3. Suggested inclusion and exclusion criteria for patients enrolled in trials to evaluate stereotactic body radiotherapy for spinal bone metastases

| Characteristic | Inclusion | Exclusion |
|--------------------|--|--|
| Radiographic | <ol style="list-style-type: none"> 1) Spinal or paraspinal metastasis by MRI (50, 51) 2) No more than 2 consecutive or 3 noncontiguous spine segments involved (50–53) | <ol style="list-style-type: none"> 1) Spinal MRI cannot be completed for any reason (50, 51) 2) Epidural compression of spinal cord or cauda equina 3) Spinal canal compromise >25% (58) 4) Unstable spine requiring surgical stabilization (50, 51, 54, 57) 5) Tumor location within 5 mm of spinal cord or cauda equina (50, 51) (relative*) |
| Patient | <ol style="list-style-type: none"> 1) Age \geq18 y (50, 54) 2) KPS of \geq40–50 (50, 51, 54, 55) 3) Medically inoperable (or patient refused surgery) (50, 51) | <ol style="list-style-type: none"> 1) Active connective tissue disease (50) 2) Worsening or progressive neurologic deficit (50–52, 57) 3) Inability to lie flat on table for SBRT (50–52) 4) Patient in hospice or with <3-month life expectancy |
| Tumor | <ol style="list-style-type: none"> 1) Histologic proof of malignancy (50, 51, 56) 2) Biopsy of spine lesion if first suspected metastasis 3) Oligometastatic or bone only metastatic disease (50) | <ol style="list-style-type: none"> 1) Radiosensitive histology such as MM⁵⁰⁻⁵² 2) Extraspinal disease not eligible for further treatment⁵¹ |
| Previous treatment | <p>Any of the following.</p> <ol style="list-style-type: none"> 1) Previous EBRT <45-Gy total dose 2) Failure of previous surgery to that spinal level (50–52) 3) Presence of gross residual disease after surgery | <ol style="list-style-type: none"> 1) Previous SBRT to same level 2) Systemic radionuclide delivery within 30 days before SBRT (50–52) 3) EBRT within 90 days before SBRT (50–52) 4) Chemotherapy within 30 days of SBRT (50–53) |



Clinical outcome: SBRT



6. Clinical Outcome after spine SBRT


Spine SBRT as primary treatment

| Study | # Pat / Tx | FU (months) | SBRT Dose | Local control |
|---------------------------------|------------|-------------|------------------|---------------|
| Ryu 2004 Henry Ford Hospital | 49 / 61 | 6 – 24 | 1 x 10-16Gy | 84% @ 1a |
| Gerszten 2007 Pittsburgh | 49 / 65 | Median 21 | 1 x 12.5 - 25Gy | 90% |
| Chang 2007 M. D. Anderson | 38 / - | Median 21 | 6 x 5Gy, 3 x 9Gy | 84% @ 1a |
| Yamada 2008 MSKCC | 93 / 103 | Median 15 | 1 x 18 – 24Gy | 90% @ 2a |
| Guckenberger 2009 Würzburg | 14 / 16 | Median 17 | 20 x 3Gy | 89% @ 2a |
| Sahgal 2009 PMH / Stanford | 14 / 23 | Median 9 | 3 x 8Gy | 78% |

Promising local control rates between 80 – 90%



Working hypothesis for a spinal SBRT program





Thank you for your attention

